Spruce Biosciences Eyes Dec 2026 TA-ERT BLA Filing
Spruce Anticipates Submitting its Trealesinidase Alfa BLA in December 2026 and amended its Avenue Loan to strengthen its balance sheet. The company also announced a separation of its CRHX-101 program into Adrenyx Biosciences.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed